Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past ...
The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell ...
The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve ...
Sarepta Therapeutics has put in place several initiatives to help its gene therapy Elevidys return to growth, but recovery ...
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder ...
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than ...
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results